65,437 trials
Dengue Fever
Primary: Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the Four Dengue Serotypes at Day 15 — 58.9; 15325.2; 5510.0; 11.2 titer
Thoracoabdominal Aortic Aneurysms
Primary: Freedom From Major Adverse Events (MAE) at Day 30 — 3; 4 Participants
Presbyopia
Primary: Subjective Overall Score — 71.4; 80.3 score on a scale
Cervical Spine Fusion
Primary: Vibrational Frequency of Vocalization Following Surgery
Postoperative Depression
Primary: Fraction of Approached Patients Who Enroll and Are Randomized — 1; 31 Participants
Cervical Radiculopathy · Cervical Spondylosis · Disk, Herniated
Primary: Percentage of Participants Reporting ≥50% Reduction in Index Numeric Rating Scale (NRS) Arm Pain Score — 19; 23; 20; 20 Participants
Substance Misuse · Suicide
Primary: Measuring Usability at Post-Gameplay — 2.73; 4.39; 4.58; 4.69 score on a scale
Head Neck Cancer
Primary: Number of Participants Achieving at Least 50% Adherence to Swallowing Exercises — 18; 17; 19; 16 Participants
Migraine With or Without Aura
Primary: Change in Monthly Migraine Days (MMD) From Baseline to the Last 28 Days of Treatment Period. — -5.67; -3.5 days — p=0.4267
COVID-19
Primary: Overall Mortality — 22; 7 Participants
Psoriasis
Primary: Investigator Global Assessment (Scalp Only) — 1.59 score on a scale
HIV/AIDS · Pre Hypertension
Primary: Change in Mean Systolic Blood Pressure (SBP) — -10.58; -4.65 mmHg — p=<0.0001
Cancer
Primary: Measure Decision Conflict Scale — 52.25; 36.86; 34.55 score on a scale — p=<0.001
Colorectal Neoplasms
Primary: Global Cohort: Overall Survival (OS) — 9.8; 9.3 Months — p=0.0379
Peripheral Arterial Disease · Peripheral Vascular Disease · Artery Disease, Peripheral
Primary: Primary Lesion Patency Though 12 Months — 82.2; 85.9 percentage of participants — p=0.0029